dabrafenib,trametinib,pembrolizumab
novartis,merck
['melanoma']
another great study examining the incorporation of #immunotherapy and targeted therapy at the neoadjuvant setting for resectable braf mutant stage iii #melanoma presented by at #asco2022 . our options to cure patients keep growing 
Medical oncologist, @lemelbaum institute for immuno-oncology. Treating patients with #Melanoma, interested in #Immunotherapy and clinical trials